Genmab’s latest update put Johnson & Johnson (JNJ) back in focus for many investors, as higher royalty income from Darzalex helped lift Genmab’s first half revenue and its full year guidance.

Against this backdrop, Johnson & Johnson’s share price sits at US$256.98, with the stock down 3.84% over the past 30 days but up 16.11% over 90 days and supported by a 53.56% 1 year total shareholder return. This suggests momentum has recently been building as investors weigh new drug progress, legal overhangs and leadership changes.

If Genmab’s Darzalex royalties have you thinking about where else growth in healthcare could come from, it may be worth scanning for other potential leaders using our healthcare focused screener for 42 healthcare AI stocks

After a strong 1 year run and a sharp move over the past quarter, the key question for Johnson & Johnson is whether the recent gains already reflect the good news or if there is still clear upside left on the table.

Most Popular Narrative: 11.3% Overvalued

According to a widely followed narrative by user Ben_Dur, Johnson & Johnson’s fair value sits at $230.82 compared with the current share price of $256.98. That gap raises clear questions about how much optimism is already reflected in the stock.

Successful AI-accelerated drug launches (oncology/immunology): multi-hundred‑million to multi‑billion revenue impact.

AI-enabled companion diagnostics & SaaS, resulting in recurring, high-margin revenue and better drug uptake/pricing.

Want to see what revenue glide path and margin profile sit behind this richer view of Johnson & Johnson. The narrative leans on compounded top line growth, firmer profitability and a future earnings multiple more often linked with faster growing sectors.

Result: Fair Value of $230.82 (OVERVALUED)

However, Johnson & Johnson’s AI upside also carries risk, including tighter regulatory scrutiny of AI evidence and rivals moving faster on differentiated platforms and data partnerships.

Another View on Johnson & Johnson’s Value

The user narrative argues that Johnson & Johnson looks 11.3% overvalued at a fair value of $230.82. In contrast, our DCF model indicates a future cash flow value of $364.27, with the stock trading 29.5% below that level. Which story do you think is closer to reality?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If sentiment on Johnson & Johnson feels mixed after these valuation contrasts, you may want to review the underlying data now and form your own perspective with 2 key rewards

Looking for more investment ideas beyond Johnson & Johnson?

If you are weighing your next move after reviewing Johnson & Johnson, do not sit on the sidelines. Use targeted stock lists to quickly surface fresh ideas aligned with your goals.

• Target income first and assess companies that may support regular cash flow using our list of potential 8 dividend fortresses.
• Hunt for quality that is not priced aggressively by checking stocks identified in our screener containing 19 high quality undiscovered gems.
• Prioritise resilience and reduce surprises by focusing on companies highlighted in our 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.